Late growth of infantile hemangiomas in children >3 years of age: A retrospective study - 14/01/19
, Elena Pope, MD, MSc c, d, Roderic J. Phillips, MD e, Francine Blei, MD, MBA f, Eulalia Baselga, MD g, Maria C. Garzon, MD h, i, Catherine McCuaig, MD j, Anita N. Haggstrom, MD k, l, Peter H. Hoeger, MD m, James R. Treat, MD n, o, Marissa J. Perman, MD n, o, Jane S. Bellet, MD p, Xavier Cubiró, MD g, Jeffrey Poole, MD q, Ilona J. Frieden, MD bAbstract |
Background |
The proliferative phase of infantile hemangiomas (IHs) is usually complete by 9 months of life. Late growth beyond age 3 years is rarely reported.
Objective |
To describe the demographic and clinic characteristics of a cohort of patients with late growth of IH, defined as growth in a patient >3 years of age.
Methods |
A multicenter, retrospective cohort study.
Results |
In total, 59 patients, 85% of which were female, met the inclusion criteria. The mean first episode of late growth was 4.3 (range 3-8.5) years. Head and neck location (55/59; 93%) and presence of deep hemangioma (52/59; 88%) were common characteristics. Posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities (PHACE) syndrome was noted in 20 of 38 (53%) children with segmental facial IH. Systemic therapy (corticosteroid or β-blocker) was given during infancy in 58 of 59 (98%) and 24 of 59 (41%) received systemic therapy (β-blockers) for late IH growth.
Limitations |
The retrospective nature and ascertainment by investigator recall are limitations of the study.
Conclusion |
Late IH growth can occur in children after 3 years of age. Risk factors include head and neck location, segmental morphology, and involvement of deep dermal/subcutaneous tissues.
Le texte complet de cet article est disponible en PDF.Key words : β-blocker, corticosteroid, growth hormone, infantile hemangioma, late growth, segmental morphology
Abbreviations used : GH, GHR, HemSCs, IH, PHACE
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Pope is an advisory board member and investigator grant recipient for Pierre Fabre. Dr Blei is a consultant, advisory board member, grant recipient, and speaker for Pierre Fabre. Dr McCuaig is an advisory board member and speaker for Pierre Fabre. Dr Poole is a speaker for Pierre Fabre. Dr Frieden has previously been a consultant for Pierre Fabre. All other authors have no conflicts of interest to disclose. |
|
| Previously presented: This work was part of a poster presentation at the 13th World Congress of Pediatric Dermatology in Chicago, Illinois, July 6-9, 2017, and the 22nd International Workshop of the International Society for the Study of Vascular Anomalies in Amsterdam, the Netherlands, May 30-June 1, 2018. |
Vol 80 - N° 2
P. 493-499 - février 2019 Retour au numéro
Article précédent
- Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States
- Fan Di Xia, Bart S. Ferket, Victor Huang, Robert S. Stern, Peggy A. Wu
- Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis
- Huilin Tang, Weilong Shi, Yiqing Song, Jiali Han
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?